Subscribe To
TARS / Tarsus Pharma: Excellent Data, Nice Execution, Unclear Market Potential
TARS News
By GlobeNewsWire
November 1, 2023
Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply prov more_horizontal
By Seeking Alpha
September 4, 2023
Tarsus Pharmaceuticals: Worthy Of A Small Bet
Tarsus Pharmaceuticals has received FDA approval for its lotilaner ophthalmic solution for the treatment of Demodex blepharitis. The company just laun more_horizontal
By The Motley Fool
July 20, 2023
Why Shares of Tarsus Pharmaceuticals Are Up Thursday
Tarsus specializes in treating eye and skin disorders. The company is still in the clinical stage but has several late-stage pipeline candidates. more_horizontal
By Zacks Investment Research
July 20, 2023
Tarsus Pharmaceuticals, Inc. (TARS) Surges 7.8%: Is This an Indication of Further Gains?
Tarsus Pharmaceuticals, Inc. (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimat more_horizontal
By GlobeNewsWire
June 5, 2023
Tarsus to Present at the Jefferies Global Healthcare Conference
IRVINE, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply prov more_horizontal
By Zacks Investment Research
April 18, 2023
Tarsus Pharmaceuticals, Inc. (TARS) Soars 8.6%: Is Further Upside Left in the Stock?
Tarsus Pharmaceuticals, Inc. (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimat more_horizontal
By Seeking Alpha
January 24, 2023
Tarsus Pharma: Excellent Data, Nice Execution, Unclear Market Potential
Tarsus ran two pivotal trials in an eye indication. Data was excellent and shows that TP-03 will help patients. more_horizontal
By Zacks Investment Research
January 24, 2023
Strength Seen in Tarsus Pharmaceuticals, Inc. (TARS): Can Its 5.0% Jump Turn into More Strength?
Tarsus Pharmaceuticals, Inc. (TARS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnin more_horizontal